TY - CHAP KW - Biomarkers KW - Blood KW - Cerebrospinal fluid KW - Huntington?s disease KW - Review KW - Urine KW - Biomarkers KW - Body Fluids KW - Brain KW - Drug Development KW - Humans KW - Huntingtin Protein KW - Huntington Disease KW - Inflammation Mediators KW - Neurons KW - Neurotransmitter Agents KW - Oxidative Stress KW - Proteomics KW - Transglutaminases T3 - Methods in Molecular Biology book series CY - New York, NY, USA T2 - Huntington?s Disease PB - Humana Press ID - discovery10049810 N2 - Huntington's disease (HD) is a chronic progressive neurodegenerative condition where new markers of disease progression are needed. So far no disease-modifying interventions have been found, and few interventions have been proven to alleviate symptoms. This may be partially explained by the lack of reliable indicators of disease severity, progression, and phenotype.Biofluid biomarkers may bring advantages in addition to clinical measures, such as reliability, reproducibility, price, accuracy, and direct quantification of pathobiological processes at the molecular level; and in addition to empowering clinical trials, they have the potential to generate useful hypotheses for new drug development.In this chapter we review biofluid biomarker reports in HD, emphasizing those we feel are likely to be closest to clinical applicability. EP - 396 AV - public ED - Precious, SV ED - Rosser, AE ED - Dunnett, SB Y1 - 2018/// TI - Biofluid Biomarkers in Huntington's Disease A1 - Rodrigues, FB A1 - Byrne, LM A1 - Wild, EJ M1 - 1780 UR - https://doi.org/10.1007/978-1-4939-7825-0_17 N1 - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions. SP - 329 ER -